Methods of treating iga nephropathy with atrasentan
MYPI2026001667A0Undetermined Publication Date: 2021-06-17CHINOOK THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2026001667
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-16
- Filing Date
- 2020-12-16
- Publication Date
- 2021-06-17
Abstract
Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and / or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV / AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.
Need to check novelty before this filing date? Find Prior Art
